However, Misale found that in vitro and in vivo, the growth of resistant cells could not be hampered by MEK1/2 inhibitors alone; instead, the synergistic pharmacological blockade of EGFR and MEK induced drawn-out ERK inhibition and serious growth impairment of resistant tumour cells [43]. Here, MAP2K7 is linked to neoplasm.